{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-027712","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.059223+00:00","generated_at":"2026-05-26T03:18:53.233453+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Standard BioTools reports Q4 pro forma revenue $46.7M, down 9% YoY; 2025 guidance $165-175M","bullets":["Q4 pro forma revenue $46.7M (down 9% YoY); full year $175.1M (down 9% YoY).","Q4 net loss $34.1M improved from $55.3M loss; adjusted EBITDA loss $18.4M (34% improvement).","Achieved $90M in operational cost synergies, exceeding original target by $10M; cash $295M, no debt.","2025 revenue guidance $165M-$175M, citing anticipated NIH funding pressure and no tariff impact.","Full year consumables revenue up 18% YoY; instruments down 27%; services down 17%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-027712","json":"https://secwatch.observer/filing/0000950170-25-027712.json","markdown":"https://secwatch.observer/filing/0000950170-25-027712.md","text":"https://secwatch.observer/filing/0000950170-25-027712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000095017025027712/0000950170-25-027712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000095017025027712/lab-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:18:53.233453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}